Dermatol. praxi. 2014;8(3):89-92

Quality of life, socio-economic aspects of venous leg ulcers and new possibilities of systemic treatment

MUDr.Veronika Slonková, Ph.D., prof.MUDr.Vladimír Vašků, CSc.
I. dermatovenerologická klinika FN u sv. Anny v Brně

Venous leg ulcers are the latest stage of chronic venous disease and represent a major health problem. They decrease quality of

life because of pain, reduced mobility and sleep disturbances. They lead to restriction of daily activities, especially leisure activities

and household duties, social isolation, employment problems, working inability, dependence on help of other people, anxiety and

depression. Because of big impact of chronic leg ulcers on quality of life, their high prevalence and their socio-economic impact it

is necessary to use all the therapeutic possibilities that can lead to faster healing of leg ulcers. Micronized purified flavonoid fraction

(MPFF) significantly reduces healing time of venous leg ulcers and it also increases the number of healed leg ulcers. According

to new international guidelines, MPFF is the only venoactive drug with proved effect in the treatment of venous leg ulcers (strong

recommendation grade 1B). Therefore, MPFF should be a basic treatment for chronic venous leg ulcers, together with adequate

compression and local therapy.

Keywords: quality of life, venous leg ulcers, venoactive drugs, micronized purified flavonoid fraction (MPFF)

Published: October 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slonková V, Vašků V. Quality of life, socio-economic aspects of venous leg ulcers and new possibilities of systemic treatment. Dermatol. praxi. 2014;8(3):89-92.
Download citation

References

  1. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997; 48: 67-69. Go to original source... Go to PubMed...
  2. Kucera Z. Leg ulcer prevalence in the Czech Republic: Omnibus survey results 2006. EWMA Journal 2006; 6(2): 28-29.
  3. Kučera Z. Prevalence a některé aspekty léčby bércových vředů v České republice. Hojení ran 2007; 1: 20-23.
  4. Price PE, Harding KG. Acute and chronic wounds: differences in self-reported health-related quality of life. J Wound Care 2000; 9: 93-95. Go to original source... Go to PubMed...
  5. Nicolaides A, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33(2): 87-208. Go to PubMed...
  6. Hyland ME, Ley A, Thomson B. Quality of life of leg ulcer patients: questionnaire and preliminary findings. J Wound Care 1994; 3: 294-298. Go to original source... Go to PubMed...
  7. Persoon A, Heinen MM, Vleuten CJM, Rooij MJ, Kerkhof PCM, Achterberg T. Leg ulcers: a review of their impact on daily life. J Clin Nurs 2004; 13: 341-354. Go to original source... Go to PubMed...
  8. Franks PJ, Moffatt CJ, Doherty DC, Smithdale R, Martin R. Longer-term changes in quality of life in chronic leg ulceration. Wound Rep Reg 2006; 14: 536-541. Go to original source... Go to PubMed...
  9. Moffatt CJ, Franks PJ, Hollinworth H. Understanding wound pain and trauma: an international perspective. EWMA Position Document: Pain at wound dressing changes 2002: 2-7.
  10. Mudge EJ, Meaume S, Woo K, Sibbald RG, Price PE. Patients´experience of wound-related pain: an international perspective. EWMA Journal 2008; 8: 19-28.
  11. Douglas V. Living with a chronic leg ulcer: an insight into patient's experience and feelings. J Wound Care 2001; 10: 355-360. Go to original source... Go to PubMed...
  12. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011; 41(1): 117-125. Go to original source... Go to PubMed...
  13. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30(2): 198-208. Go to original source... Go to PubMed...
  14. Roztočil K, Štvrtinová V, Strejček J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22(1): 1-8. Go to PubMed...
  15. Glinski W, et al. The beneficial augmentative effect of micronised purified flavonoid fraction (MPFF) on the healing of leg ulcers: an open, multicentre, controlled, randomised study. Phlebology 1999; 14: 151-157. Go to original source...
  16. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology 2002; 53(3): 245-256. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.